7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

7 Hills Pharma announces the expansion of its patent portfolio with new claims covering innovative integrin agonist combination therapies. The newly issued patent no. 11,311,619 strengthens 7HP’s leadership in leveraging integrin activation to overcome immunotherapy resistance, expanding applications across diverse therapeutic areas.

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.

7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.

Discover how 7 Hills Pharma’s integrin activators enhance immunotherapies by boosting cell adhesion, improving COVID-19 vaccines, checkpoint inhibitors, and cancer treatments. Learn more from BIO Digital 2020.

7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.

7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.

7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.